These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30098331)

  • 1. Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation.
    Dietrich M; Malik MS; Nikolaysen F; Skeie M; Stang E
    Exp Cell Res; 2018 Oct; 371(1):139-150. PubMed ID: 30098331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
    Bailey TA; Luan H; Tom E; Bielecki TA; Mohapatra B; Ahmad G; George M; Kelly DL; Natarajan A; Raja SM; Band V; Band H
    J Biol Chem; 2014 Oct; 289(44):30443-30458. PubMed ID: 25225290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
    Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
    Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C regulates ErbB3 turnover.
    Dietrich M; Malik MS; Skeie M; Bertelsen V; Stang E
    Exp Cell Res; 2019 Sep; 382(2):111473. PubMed ID: 31233741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
    Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
    J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.
    Cortese K; Howes MT; Lundmark R; Tagliatti E; Bagnato P; Petrelli A; Bono M; McMahon HT; Parton RG; Tacchetti C
    Mol Biol Cell; 2013 Jan; 24(2):129-44. PubMed ID: 23154999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
    Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
    Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preubiquitinated chimeric ErbB2 is constitutively endocytosed and subsequently degraded in lysosomes.
    Vuong TT; Berger C; Bertelsen V; Rødland MS; Stang E; Madshus IH
    Exp Cell Res; 2013 Feb; 319(3):32-45. PubMed ID: 23127513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
    Barr DJ; Ostermeyer-Fay AG; Matundan RA; Brown DA
    J Cell Sci; 2008 Oct; 121(Pt 19):3155-66. PubMed ID: 18765569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB2 degradation mediated by the co-chaperone protein CHIP.
    Zhou P; Fernandes N; Dodge IL; Reddi AL; Rao N; Safran H; DiPetrillo TA; Wazer DE; Band V; Band H
    J Biol Chem; 2003 Apr; 278(16):13829-37. PubMed ID: 12574167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair.
    Bruns AF; Yuldasheva N; Latham AM; Bao L; Pellet-Many C; Frankel P; Stephen SL; Howell GJ; Wheatcroft SB; Kearney MT; Zachary IC; Ponnambalam S
    PLoS One; 2012; 7(11):e48539. PubMed ID: 23139789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
    Marx C; Held JM; Gibson BW; Benz CC
    Cancer Res; 2010 May; 70(9):3709-17. PubMed ID: 20406983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.
    Xu W; Mimnaugh EG; Kim JS; Trepel JB; Neckers LM
    Cell Stress Chaperones; 2002 Jan; 7(1):91-6. PubMed ID: 11892991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained activation of protein kinase C downregulates nuclear factor-kappaB signaling by dissociation of IKK-gamma and Hsp90 complex in human colonic epithelial cells.
    Park KA; Byun HS; Won M; Yang KJ; Shin S; Piao L; Kim JM; Yoon WH; Junn E; Park J; Seok JH; Hur GM
    Carcinogenesis; 2007 Jan; 28(1):71-80. PubMed ID: 16774932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells.
    Suzuki T; Fujii A; Ochi H; Nakamura H
    J Cell Biochem; 2011 Sep; 112(9):2279-86. PubMed ID: 21503962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.